Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domperidone for improving time in range in asymptomatic type 1 diabetes with delayed gastric emptying
2024-514838-20-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of domperidone in diabetes mellitus type 1 (T1D) and gastroparesis (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Time in range over 14 days. Planned start Aug 2026; status: authorised.
02
Drugs
domperidone
03
Conditions
diabetes mellitus type 1 (T1D)gastroparesis
Beyond the preview
Go deeper on 2024-514838-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514838-20-00.